Current
11.1×
5-Year Average
19.1×
All-Time High
10119.6×
All-Time Low
6.5×
P/FCF Ratio daily chart for Biogen (BIIB)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/FCF Ratio for Biogen (BIIB) from 2001 to 2025
| 2025 | $25.82B | $2.14B | 12.1× | +3.2× | |
| 2024 | $22.28B | $2.52B | 8.9× | -21.4× | |
| 2023 | $37.50B | $1.24B | 30.2× | -4.8× | |
| 2022 | $39.90B | $1.14B | 35.0× | +24.4× | |
| 2021 | $35.24B | $3.35B | 10.5× | +0.6× | |
| 2020 | $37.63B | $3.79B | 9.9× | +1.9× | |
| 2019 | $52.76B | $6.56B | 8.0× | -3.3× | |
| 2018 | $60.12B | $5.30B | 11.3× | -14.7× | |
| 2017 | $67.38B | $2.59B | 26.0× | +9.8× | |
| 2016 | $61.42B | $3.79B | 16.2× | -5.8× | |
| 2015 | $67.52B | $3.07B | 22.0× | -8.1× | |
| 2014 | $79.93B | $2.65B | 30.1× | — | |
| 2013 | $66.06B | −$1.16B | — | — | |
| 2012 | $34.63B | $1.62B | 21.4× | +3.6× | |
| 2011 | $26.74B | $1.51B | 17.8× | +6.6× | |
| 2010 | $16.19B | $1.45B | 11.2× | -4.7× | |
| 2009 | $14.44B | $909.25M | 15.9× | +5.2× | |
| 2008 | $13.70B | $1.29B | 10.6× | -12.3× | |
| 2007 | $16.86B | $736.53M | 22.9× | -3.1× | |
| 2006 | $16.74B | $642.96M | 26.0× | -0.9× | |
| 2005 | $15.38B | $571.13M | 26.9× | -35.4× | |
| 2004 | $22.33B | $358.22M | 62.3× | — | |
| 2003 | $12.25B | −$82.03M | — | — | |
| 2002 | $12.94B | $45.52M | 284.2× | +61.7× | |
| 2001 | $26.88B | $120.82M | 222.5× | — |
- 202512.1×
- 20248.9×
- 202330.2×
- 202235.0×
- 202110.5×
- 20209.9×
- 20198.0×
- 201811.3×
- 201726.0×
- 201616.2×
- 201522.0×
- 201430.1×
- 2013—
- 201221.4×
- 201117.8×
- 201011.2×
- 200915.9×
- 200810.6×
- 200722.9×
- 200626.0×
- 200526.9×
- 200462.3×
- 2003—
- 2002284.2×
- 2001222.5×
About P/FCF Ratio at Biogen (BIIB)
Biogen (BIIB) P/FCF ratio is 11.1× as of June 5, 2026. The 5-year average is 19.1×. The sector median currently stands at 19.8×. The current ratio is at the 23th percentile of its own 10-year history.
Biogen (BIIB) historical P/FCF ratio has ranged from a low of 6.5× (2020) to a high of 10119.6× (2002) in the available daily series.
The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.
Biogen P/FCF Ratio by Year
Biogen P/FCF Ratio 2025: 12.1×
Biogen (BIIB) P/FCF ratio in 2025 was 12.1×, expanded from 8.9× the prior year.
Biogen P/FCF Ratio 2024: 8.9×
Biogen (BIIB) P/FCF ratio in 2024 was 8.9×, contracted from 30.2× the prior year.
Biogen P/FCF Ratio 2023: 30.2×
Biogen (BIIB) P/FCF ratio in 2023 was 30.2×, contracted from 35.0× the prior year.
Biogen P/FCF Ratio 2022: 35.0×
Biogen (BIIB) P/FCF ratio in 2022 was 35.0×, expanded from 10.5× the prior year.
Biogen P/FCF Ratio 2021: 10.5×
Biogen (BIIB) P/FCF ratio in 2021 was 10.5×.
Sector peers by P/FCF Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/FCF Ratio — table
Healthcare peers of Biogen (BIIB), ranked by P/FCF ratio.
| 18.5× | |
| 17.8× | |
| 17.8× | |
| 16.9× | |
| 16.9× | |
| 16.7× | |
| 16.4× | |
| 16.3× | |
| 15.9× | |
| 14.0× | |
| 13.5× | |
| 12.9× | |
| 12.5× | |
| 12.4× | |
| 12.2× | |
| 12.1× | |
| 11.3× | |
| 10.7× | |
| 10.4× | |
| 10.0× | |
| 9.6× | |
| 9.1× | |
| 9.1× | |
| 6.9× | |
| 2.5× |
- 18.5×
- 17.8×
- 16.9×
- 16.7×
- 16.4×
- 13.5×
- 12.9×
- 12.4×
- 10.7×
- 9.1×
- 9.1×
- 6.9×
- 2.5×
Frequently asked questions
Biogen (BIIB) Key Financials
Charts, filings, and peer comparison for every metric